10-KPeriod: FY2024

BIOGEN INC. Annual Report, Year Ended Dec 31, 2024

Filed February 12, 2025For Securities:BIIB

Summary

Biogen Inc.'s (BIIB) 10-K filing for the year ending December 31, 2024, highlights a company navigating a challenging market for its Multiple Sclerosis (MS) portfolio, which saw significant revenue decline primarily due to increased competition and a shift towards higher efficacy therapies. This decline was partially offset by growth in the Rare Disease segment, driven by new product launches like SKYCLARYS and QALSODY. The company made strategic moves, including the $1.15 billion acquisition of HI-Bio to bolster its immunology pipeline with felzartamab. Looking ahead, Biogen is focused on key pipeline advancements, including the ongoing development and regulatory submissions for LEQEMBI in Alzheimer's disease and pipeline expansion in neurology, specialized immunology, and rare diseases. The company is also implementing cost-reduction measures through its "Fit for Growth" program to improve efficiency. Investors should monitor Biogen's ability to successfully commercialize its newer assets, manage the decline in its established MS franchise, and navigate the competitive landscape, especially with the increasing impact of biosimilars and generic competition on products like TECFIDERA and TYSABRI.

Financial Highlights

53 data points
Beta

Revenue

$9.68B

76.1% Gross Margin

Net Income

$1.63B

16.9% Net Margin

EPS (Diluted)

$11.18

Total Assets

$28.05B

Cash & Equivalents

$2.38B

Free Cash Flow

$2.72B

Financial Statements
Beta
Revenue$9.68B
Cost of Revenue$2.31B
Gross Profit$7.37B
SG&A Expenses$2.40B
Operating Expenses$7.77B
Interest Expense$250.30M
Net Income$1.63B
EPS (Basic)$11.21
EPS (Diluted)$11.18
Shares Outstanding (Basic)145.60M
Shares Outstanding (Diluted)145.90M

Key Highlights

  • 1Biogen's Multiple Sclerosis (MS) franchise revenue decreased by 6.7% year-over-year due to increased competition and a market shift towards more effective treatments.
  • 2The Rare Disease segment showed strong growth, with revenue increasing by 10.3%, primarily driven by new product launches such as SKYCLARYS ($382.5 million in 2024) and QALSODY.
  • 3The company completed the acquisition of HI-Bio for $1.15 billion, adding felzartamab, an anti-CD38 antibody, to its pipeline, aimed at enhancing its immunology and rare disease capabilities.
  • 4LEQEMBI, Biogen's Alzheimer's disease treatment developed in collaboration with Eisai, saw significant regulatory developments, including FDA approval for monthly IV maintenance dosing and acceptance of a BLA for a subcutaneous autoinjector.
  • 5Biogen continues to face significant generic and biosimilar competition for its established products like TECFIDERA and TYSABRI, which is expected to continue impacting revenue.
  • 6The company is implementing cost-reduction initiatives through its "Fit for Growth" program, aiming for approximately $1.0 billion in gross operating expense savings by the end of 2025.
  • 7Cash and cash equivalents increased significantly to $2.375 billion from $1.05 billion, partly due to the sale of its equity interest in Samsung Bioepis and cash generated from operations, though also impacted by the HI-Bio acquisition and debt repayment.

Frequently Asked Questions

Biogen's total revenue decreased by 1.6% ($159.7 million). The primary driver for this decrease was a 6.7% decline in Multiple Sclerosis (MS) product revenue, totaling $312.1 million, due to increased competition and patient shifts to alternative therapies for products like TYSABRI and TECFIDERA. This was partially offset by a 10.3% increase in Rare Disease revenue, driven by new product launches like SKYCLARYS, QALSODY, and ZURZUVAE, contributing $185.1 million.

Biogen and its partner Eisai made significant progress with LEQEMBI. In January 2025, the FDA approved monthly IV maintenance dosing for early Alzheimer's disease. Additionally, the FDA accepted a Biologics License Application (BLA) for a subcutaneous autoinjector for weekly maintenance dosing, with a decision expected by August 31, 2025. Clinical data presented throughout 2024 indicated that three years of continuous LEQEMBI treatment resulted in reduced clinical decline.

Biogen is facing headwinds in its MS portfolio due to increasing competition from generics, biosimilars, and newer, more effective therapies. The company expects continued revenue decline in this segment. To mitigate this, Biogen is focusing on its pipeline and strategic acquisitions, such as HI-Bio, to diversify its revenue streams and build expertise in other therapeutic areas like immunology and rare diseases. Cost-reduction measures through the "Fit for Growth" program are also being implemented.

Biogen completed the acquisition of HI-Bio in July 2024 for approximately $1.15 billion. This acquisition aims to strengthen Biogen's pipeline in immunology and rare diseases, specifically adding felzartamab, an anti-CD38 antibody, which has received Breakthrough Therapy Designation for certain indications. This strategic move is part of Biogen's efforts to expand its portfolio beyond its traditional MS focus.